The AGRANA Research
bit.bio discovery combines single cell functional genomics with best-in-class cellular models to decipher complex cellular pathways and gain a better understanding of disease development. This next-generation CRISPR screening platform will help to understand the role of gene networks at unprecedented scale and resolution to discover and validate novel drug targets.
Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens.
Aposcience AG is unique in having developed a secretome-based regenerative therapy. The secretome is produced under GMP-conditions and was approved by the Austrian regulatory agency for a clinical phase II trial. Our product platform Aposec consists of two products: APO-1 - Aposec for internal diseases (acute myocardial infarction, spinal cord injury and stroke) APO-2 - Aposec for topical application (hard-healing wounds, diabetic ulcers)
YASARA Biosciences develops and distributes the YASARA molecular modelling and simulation program. This acronym stands for Yet Another Scientific Artificial Reality Application, and delineates the software's main purpose: to create an artificial reality inside the computer, atom by atom, visualize it in 3D and let the user interact with it. The focus has always been on biomolecular modelling, covering the most prominent topics (including structure prediction and docking).
Acticell is a research company that develops innovative solutions for new trends in the textile industry. The research and technology start-up has specialized in the field of cellulose chemistry, especially in the textile industry. Acticell know-how can replace life-threatening sandblasting and the environmentally harmful potassium permanganate in bleaching jeans. Worldwide leading jeans labels already rely on production processes with Acticell technology.
Brain Implant Therapeutics (BIT) Pharma was founded in November 2015 by leaders from academia and industry. The company resides in Graz, Austria. BIT Pharma develops and commercializes technologies for site-specific drug delivery to the central nervous system (CNS), in particular the brain, exploiting tailored drug delivery systems.
Ares Genetics is a sequencing service provider and bioinformatics developer revolutionizing how we address the global challenge of antimicrobial resistance (AMR). Ares Genetics enables better infection control and more targeted patient care by providing unprecedented insight into pathogens and AMR through next generation sequencing (NGS) and artificial intelligence (AI) powered solutions.
NBS-C BioScience is a Contract Research Laboratory founded 2009 as a spin off by leading scientists of the Novartis Institutes for BioMedical Research in Vienna, Austria. In a second business field NBS-C BioScience develops and commercializes research tools and kit components for allergy research and diagnostics.
usePAT offers add-on devices for the improvement of in-line measurements in PAT (Process Analytical Technology) systems. They are compatible with a variety of sensors and can be designed and adapted to the specific needs and requirements of many fields of application. In order to facilitate the process of real-time measuring, our technology takes advantage of well-controlled ultrasonic fields for spatial particle manipulation in liquids.
Fresenius Kabi Austria, ist ein Tochterunternehmen des internationalen Gesundheitskonzerns Fresenius Kabi. Fresenius Kabi ist spezialisiert auf intravenös zu verabreichende generische Arzneimittel, Infusionstherapie und klinische Ernährung. Die Aktivitäten umfassen Entwicklung, Herstellung und Vertrieb von Produkten, die zur Verbesserung der Lebensqualität chronisch und kritisch kranker Patienten im Krankenhaus und im außerklinischen Bereich beitragen.
EURRUS Biotech GmbH ("Eurrus") is incorporated in Tulln, Austria. Founded in 2006 the existing partners joined in 2012. Development focus is Asthma with a newly developed API. Development status has reached CP IIb.
Pregenerate GmbH is a Vienna- based medtech startup established in November, 2019 with an aim to improve treatment outcomes for osteoarthritis patients by in vitro monitoring of cellular responses to different therapeutics. The Pregenerate team consists of five full time employees with extensive academic and clinical experience, as well as years of expertise in the pharmaceutical industry.
enGenes Biotech develops customized solutions for the cost-effective production of recombinant proteins and plasmid DNA in microbial expression systems. The company’s unique, proprietary, E. coli-based enGenes-X-press technology platform achieves outstanding yields of soluble and active recombinant protein or plasmid DNA by reducing biological complexity. This is achieved by decoupling biomass growth from product formation.
Based on a highly innovative therapeutic concept ProFem develops new medicines for gynecological diseases which are characterized by a hitherto unmet medical need and high market potential. ProFem’s activities are currently focused on infectious diseases of the female lower genitourinary tract associated with the growth of biofilms.
VelaLabs services as a GLP and GMP certified and G(C)LP compliant contract laboratory cover analytical services for Biologics (ATMPs, Biopharmaceuticals, Originator products, Biosimilar Candidates, Biosimilars, Blood and blood components, Vaccines), Chemicals and Excipients from early stages of product development (non-clinical, clinical) until market release testing for Pharma and Biotech companies as well as storage facilities enabling long term stability studies.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
GENSPEED Biotech GmbH was founded in October 2016 as a spin-off of Greiner Bio-One. We develop, produce and distribute rapid tests based on the IVD-CE certified GENSPEED® technology. With a novel combination of microfluidics, miniaturized optical detection and automation, GENSPEED® allows for the first time to detect a multiple of parameters simultaneously and with high sensitivity at the point of care (POC) in just a few minutes.